Reference Detail

Ref Type

Journal Article

PMID

(38978737)

Authors

Xiong J, Xia L

Title

Case report: Precise NGS and combined bevacizumab promote durable response in ALK-positive lung adenocarcinoma with multiple-line ALK-TKI resistance.

Journal	Vol	Issue	Date	Pages	Journal Short Title
Frontiers in oncology	14		2024	1419306	Front Oncol

URL

Abstract Text

Liquid biopsies including pleural fluid or plasma are commonly applied for patients with advanced non-small cell lung cancer (NSCLC) and pleural effusion (PE) to guide the treatment. ALK-TKIs are the first options for patients with ALK-positive mutations and combining ALK-TKIs with angiogenic agents may improve survival. We report here one case with ALK-positive lung adenocarcinoma in which the patient achieved a prolonged progression-free survival (PFS) of 97 months after undergoing precise pleural effusion NGS and receiving combined bevacizumab treatment following multiple-line ALK-TKI resistance.

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile	Treatment Approach

Gene Name	Source	Synonyms	Protein Domains	Gene Description	Gene Role

Therapy Name	Drugs	Efficacy Evidence	Clinical Trials

Drug Name	Trade Name	Synonyms	Drug Classes	Drug Description

Gene	Variant	Impact	Protein Effect	Variant Description	Associated with drug Resistance

Molecular Profile	Indication/Tumor Type	Response Type	Therapy Name	Approval Status	Evidence Type	Efficacy Evidence	References
EML4 - ALK ALK F1174C ALK V1180L	lung adenocarcinoma	predicted - resistant	Alectinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with lung adenocarcinoma harboring EML4-ALK (e6:e20) and ALK F1174C progressed on treatment with Alecensa (alectinib) and was found to have acquired ALK V1180L (PMID: 38978737).	38978737
EML4 - ALK ALK F1174C ALK V1180L	lung adenocarcinoma	predicted - sensitive	Bevacizumab + Lorlatinib	Case Reports/Case Series	Actionable	In a clinical case study, treatment with the combination of Lorbrena (lorlatinib) and Avastin (bevacizumab) resulted in a partial response and a progression-free survival of 33 months in a patient with lung adenocarcinoma harboring EML4-ALK (e6:e20) with ALK F1174C and V1180L (PMID: 38978737).	38978737
EML4 - ALK	lung adenocarcinoma	predicted - sensitive	Crizotinib	Case Reports/Case Series	Actionable	In a clinical case study, Xalkori (crizotinib) treatment resulted in a complete response and a progression-free survival of 35 months in a patient with lung adenocarcinoma harboring EML4-ALK (e6:e20) (PMID: 38978737).	38978737
EML4 - ALK ALK F1174C	lung adenocarcinoma	predicted - resistant	Crizotinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with lung adenocarcinoma harboring EML4-ALK (e6:e20) progressed on treatment with Xalkori (crizotinib) and was found to have acquired ALK F1174C (PMID: 38978737).	38978737
EML4 - ALK ALK F1174C	lung adenocarcinoma	predicted - sensitive	Alectinib	Case Reports/Case Series	Actionable	In a clinical case study, Alecensa (alectinib) treatment resulted in a complete response and a progression-free survival of 29 months in a patient with lung adenocarcinoma harboring EML4-ALK (e6:e20) with ALK F1174C (PMID: 38978737).	38978737